Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Idera Pharmaceutical (IDRA)

1.62 -0.1 (-5.81%)

04-20 16:00

Open:

1.7

Pre. Close:

1.72

High:

1.71

Low:

1.605

Volume:

1,382,803

Market Cap:

350M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

1.713 - 1.723

1.723 - 1.734

Low:

1.584 - 1.594

1.594 - 1.605

Close:

1.6 - 1.618

1.618 - 1.638

Technical analysis  (as of: 2018-04-20 4:30:43 PM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 2.19     One year: 2.42

Support:

Support1: 1.57    Support2: 1.31

Resistance:

Resistance1: 1.88    Resistance2: 2.07

Pivot:

1.71

Moving Averages:

MA(5): 1.73     MA(20): 1.77

MA(100): 1.98     MA(250): 1.96

MACD:

MACD(12,26): -0.05     Signal(12,26,9): -0.05

%K %D:

%K(14,3): 35.71     %D(3): 40.35

RSI:

RSI(14): 38.26

52-Week:

High: 2.87  Low: 1.32  Change(%): -28.0

Average Vol(K):

3-Month: 145530  10-Days 82453

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
IDRA has closed above bottom band by 17.5%. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-04-10T08:19:35-04:00
BioCryst and Idera postpone shareholder meetings for merger vote until July 10

2018-04-10T07:30:00-04:00
BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger

2018-03-07T07:35:19-05:00
Idera Pharmaceuticals beats by $0.01, beats on revenue

2018-03-05T05:39:51-05:00
Biotech Analysis Central Pharma News: Biogen Pulls MS Drug, Roche's And Ionis' Huntington's Drug Advance, Idera's Hope

2018-03-04T10:34:38-05:00
3 Things In Biotech, March 3, 2018: FibroGen's Fast, INSYS Progresses, Idera Moves

2018-03-02T08:00:00-05:00
Your Daily Pharma Scoop: Portola Drops On AndexXa Update, NovaVax Top-Line Results, Idera Commences Late-Stage Study With IMO-2125

2018-03-01T07:39:12-05:00
Idera Pharma launches late-stage study of IMO-2125 in treatment-resistant melanoma

2018-02-26T05:58:42-05:00
Meet The Team: The King Is Dead. Long Live The King! - Part IV

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology Medical Research

Shares Out. (M)

195.69

Shares Float (M)

193.85

% Held by Insiders

0.90

% Held by Institutions

35.20

Shares Short (K)

2833

Shares Short Prior Month (K)

3060

Stock Financials

EPS

-0.420

EPS Est. Current Year

-0.480

EPS Est. Next Year

-0.500

EPS Est. Next Quarter

-0.120

Forward EPS

-0.459

Book Value (p.s.)

3.400

PEG Ratio

Profit Margin

Operating Margin

-6750.55

Return on Assets (ttm)

-57.0

Return on Equity (ttm)

-62.5

Qtrly Rev. Growth

-98.9

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.258

Qtrly Earnings Growth

Operating Cash Flow (M)

-55.26

Levered Free Cash Flow (M)

-27.80

atoplab.com

Valuation

P/E

-3.86

P/E Growth Ratio

-0.06

P/BV

0.48

P/S

34992001024.00

P/CF

-5.74

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.